Journal ArticleDOI
EAACI/GA(2)LEN/EDF/WAO guideline: management of urticaria.
Torsten Zuberbier,Riccardo Asero,Carsten Bindslev-Jensen,G. Walter Canonica,Martin K. Church,Ana Giménez-Arnau,Clive Grattan,Alexander Kapp,Marcus Maurer,Hans F. Merk,Barbara Rogala,Sarbjit S. Saini,Mario Sánchez-Borges,Peter Schmid-Grendelmeier,Holger J. Schünemann,Petra Staubach,Gino A. Vena,Bettina Wedi +17 more
Reads0
Chats0
TLDR
This guideline has a profound impact on the quality of life and effective treatment is, therefore, required and the recommended first line treatment is new generation, nonsedating H1‐antihistamines, and second‐line therapies should be added to the antihistamine treatment.Abstract:
This guideline, together with its sister guideline on the classification of urticaria (Zuberbier T, Asero R, Bindslev-Jensen C, Canonica GW, Church MK, Gimenez-Arnau AM et al. EAACI/GA(2)LEN/EDF/WAO Guideline: definition, classification and diagnosis of urticaria. Allergy 2009;64: 1417-1426), is the result of a consensus reached during a panel discussion at the Third International Consensus Meeting on Urticaria, Urticaria 2008, a joint initiative of the Dermatology Section of the European Academy of Allergology and Clinical Immunology (EAACI), the EU-funded network of excellence, the Global Allergy and Asthma European Network (GA(2)LEN), the European Dermatology Forum (EDF) and the World Allergy Organization (WAO). As members of the panel, the authors had prepared their suggestions regarding management of urticaria before the meeting. The draft of the guideline took into account all available evidence in the literature (including Medline and Embase searches and hand searches of abstracts at international allergy congresses in 2004-2008) and was based on the existing consensus reports of the first and the second symposia in 2000 and 2004. These suggestions were then discussed in detail among the panel members and with the over 200 international specialists of the meeting to achieve a consensus using a simple voting system where appropriate. Urticaria has a profound impact on the quality of life and effective treatment is, therefore, required. The recommended first line treatment is new generation, nonsedating H(1)-antihistamines. If standard dosing is not effective, increasing the dosage up to four-fold is recommended. For patients who do not respond to a four-fold increase in dosage of nonsedating H(1)-antihistamines, it is recommended that second-line therapies should be added to the antihistamine treatment. In the choice of second-line treatment, both their costs and risk/benefit profiles are most important to consider. Corticosteroids are not recommended for long-term treatment due to their unavoidable severe adverse effects. This guideline was acknowledged and accepted by the European Union of Medical Specialists (UEMS).read more
Citations
More filters
Journal ArticleDOI
The EAACI/GA(2) LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update.
Torsten Zuberbier,Werner Aberer,Riccardo Asero,Carsten Bindslev-Jensen,Zenon Brzoza,Giorgio Walter Canonica,Martin K. Church,Luis Felipe Ensina,Ana Giménez-Arnau,Kiran Godse,Margarida Gonçalo,Clive Grattan,Jacques Hébert,Michihiro Hide,Allen P. Kaplan,Alexander Kapp,A H Abdul Latiff,P. Mathelier-Fusade,Martin Metz,Alexander Nast,Sarbjit S. Saini,Mario Sánchez-Borges,Peter Schmid-Grendelmeier,F. E. R. Simons,Petra Staubach,Gordon Sussman,Elias Toubi,Gino A. Vena,Bettina Wedi,X J Zhu,Markus Maurer +30 more
TL;DR: This guideline covers the definition and classification of urticaria, taking into account the recent progress in identifying its causes, eliciting factors and pathomechanisms, and outlines evidence-based diagnostic and therapeutic approaches for the different subtypes ofUrticaria.
Journal ArticleDOI
The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria.
Torsten Zuberbier,Werner Aberer,Riccardo Asero,A H Abdul Latiff,Diane Baker,Barbara Ballmer-Weber,Jonathan A. Bernstein,Carsten Bindslev-Jensen,Zenon Brzoza,R Buense Bedrikow,G.W. Canonica,Martin K. Church,Timothy J. Craig,I V Danilycheva,Corinna Dressler,Luis Felipe Ensina,Ana Giménez-Arnau,Kiran Godse,Margarida Gonçalo,Clive Grattan,Jacques Hébert,Michihiro Hide,Allen P. Kaplan,Alexander Kapp,C. Katelaris,Emek Kocatürk,Kanokvalai Kulthanan,D. Larenas-Linnemann,Tabi A. Leslie,Markus Magerl,P. Mathelier-Fusade,R. Y. Meshkova,Martin Metz,Alexander Nast,Eustachio Nettis,Hanneke Oude-Elberink,Stefanie Rosumeck,Sarbjit S. Saini,Mario Sánchez-Borges,Peter Schmid-Grendelmeier,Petra Staubach,Gordon Sussman,Elias Toubi,Gino A. Vena,Christian Vestergaard,Bettina Wedi,Ricardo Niklas Werner,Zuotao Zhao,Marcus Maurer +48 more
TL;DR: In this paper, an evidence-and consensus-based guideline was developed following the methods recommended by Cochrane and the Grading of Recommendations Assessment, Development and Evaluation (GRADE) working group.
Journal ArticleDOI
Omalizumab for the Treatment of Chronic Idiopathic or Spontaneous Urticaria
Marcus Maurer,Karin Rosén,Hsin-Ju Hsieh,Sarbjit S. Saini,Clive Grattan,Ana Giménez-Arnau,Sunil Agarwal,Ramona Doyle,Janice Canvin,Allen P. Kaplan,Thomas B. Casale +10 more
TL;DR: Omalizumab diminished clinical symptoms and signs of chronic idiopathic urticaria in patients who had remained symptomatic despite the use of approved doses of H-antihistamine therapy (licensed doses).
Journal ArticleDOI
Unmet clinical needs in chronic spontaneous urticaria. A GA²LEN task force report.
Marcus Maurer,Karsten Weller,Carsten Bindslev-Jensen,Ana Giménez-Arnau,P. J. Bousquet,Jean Bousquet,G.W. Canonica,M. K. Church,M. K. Church,Kiran Godse,Clive Grattan,Malcolm W. Greaves,Michihiro Hide,Dimitris Kalogeromitros,Allen P. Kaplan,Sarbjit S. Saini,X J Zhu,T. Zuberbier +17 more
TL;DR: A GA2LEN task force report concluded that chronic spontaneous urticaria is a “hidden epidemic” that needs to be addressed to address the unmet clinical needs of patients.
Journal ArticleDOI
Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy
Allen P. Kaplan,Dennis K. Ledford,Mark Ashby,Janice Canvin,James L. Zazzali,Edward Conner,Joachim Veith,Nikhil Kamath,Petra Staubach,Thilo Jakob,Robert G Stirling,Piotr Kuna,William E. Berger,Marcus Maurer,Karin Rosén +14 more
TL;DR: In this paper, the authors evaluated the safety and efficacy of 24 weeks of treatment with omalizumab in patients with persistent chronic idiopathic urticaria/chronic spontaneous urticria (CIU/CSU) despite treatment with H 1 -antihistamines at up to 4 times the approved dose plus H 2 -antiHistamines, leukotriene receptor antagonists, or both.
References
More filters
Journal ArticleDOI
GRADE: an emerging consensus on rating quality of evidence and strength of recommendations
Gordon H. Guyatt,Andrew D Oxman,Gunn Elisabeth Vist,Regina Kunz,Yngve Falck-Ytter,Pablo Alonso-Coello,Holger J. Schünemann +6 more
TL;DR: The advantages of the GRADE system are explored, which is increasingly being adopted by organisations worldwide and which is often praised for its high level of consistency.
Journal ArticleDOI
What is “quality of evidence” and why is it important to clinicians?
Gordon H. Guyatt,Andrew D Oxman,Regina Kunz,Gunn Elisabeth Vist,Yngve Falck-Ytter,Holger J. Schünemann +5 more
TL;DR: Guideline developers use a bewildering variety of systems to rate the quality of the evidence underlying their recommendations as mentioned in this paper, some are facile, some confused, and others sophisticated but complex.
Journal ArticleDOI
Going from evidence to recommendations
Gordon H. Guyatt,Andrew D Oxman,Regina Kunz,Yngve Falck-Ytter,Gunn Elisabeth Vist,Alessandro Liberati,Holger J. Schünemann +6 more
TL;DR: The GRADE system classifies recommendations made in guidelines as either strong or weak, and the meaning of these descriptions and their implications for patients, clinicians, and policy makers are explored.
Journal ArticleDOI
EAACI/GA(2)LEN/EDF/WAO guideline: definition, classification and diagnosis of urticaria.
T. Zuberbier,Riccardo Asero,Carsten Bindslev-Jensen,G. Walter Canonica,Martin K. Church,Ana Giménez-Arnau,Clive Grattan,Alexander Kapp,Hans F. Merk,Barbara Rogala,Sarbjit S. Saini,Mario Sánchez-Borges,Peter Schmid-Grendelmeier,Holger J. Schünemann,Petra Staubach,Gino A. Vena,Bettina Wedi,Marcus Maurer +17 more
TL;DR: This guideline covers the definition and classification of urticaria, taking into account the recent progress in identifying its causes, eliciting factors, and pathomechanisms, and outlines evidence‐based diagnostic approaches for different subtypes ofUrticaria.
Journal ArticleDOI
The impact of chronic urticaria on the quality of life
TL;DR: The patients with DPU had significantly more problems with mobility, gardening and choice of clothing than the uncomplicated CU patients, and suffered more pain, had more issues with work and were more restricted in their hobbies.
Related Papers (5)
EAACI/GA(2)LEN/EDF/WAO guideline: definition, classification and diagnosis of urticaria.
T. Zuberbier,Riccardo Asero,Carsten Bindslev-Jensen,G. Walter Canonica,Martin K. Church,Ana Giménez-Arnau,Clive Grattan,Alexander Kapp,Hans F. Merk,Barbara Rogala,Sarbjit S. Saini,Mario Sánchez-Borges,Peter Schmid-Grendelmeier,Holger J. Schünemann,Petra Staubach,Gino A. Vena,Bettina Wedi,Marcus Maurer +17 more